The furore over Avandia (rosiglitazone), GlaxoSmithKline's blockbuster drug for diabetes, illustrates how ... Agency for the Evaluation of Medicinal Products (EMEA) moved more quickly, and in ...

GlaxoSmithKline is in a spree of producing new diabetes and cancer drugs which it hopes will increase its sales this year. After the recent U.S. drug approvals it is starting to market two of its ...

GlaxoSmithKline's approval review date for its diabetes drug has been pushed back by three months by the US Food and Drug Administration (FDA). The US Prescription Drug User Fee Act goal date for ...

The US Food and Drug Administration is to remove certain restrictions on prescribing and use of GlaxoSmithKline's diabetes drug, Avandia (rosiglitazone). This decision was made to reflect new ...